Fidaxomicin Reduces Collagen Expression in Intestinal Fibroblasts Via Platelet-Derived Growth Factor Receptor Beta and Glycogen Synthase Kinase-3 Beta Inhibition
Fidaxomicin inhibits intestinal fibrosis by reducing PDGFRβ phosphorylation and expression, GSK3β phosphorylation, and collagen expression in intestinal fibroblasts.
Authors
- Rebecca Park
- Florian Rieder (ORCID: https://orcid.org/0000-0002-9087-1568)
- Sophie Irwin (ORCID: https://orcid.org/0000-0002-2821-8015)
- Becca Nelson (ORCID: https://orcid.org/0000-0001-7338-3215)
- M Daelen (ORCID: https://orcid.org/0009-0008-7521-3111)
- Berkeley N. Limketkai (ORCID: https://orcid.org/0000-0003-2714-6934)
- Hon Wai Koon (ORCID: https://orcid.org/0000-0003-0618-0869)
- Swapna Mahurkar‐Joshi (ORCID: https://orcid.org/0000-0001-9591-4590)
- David Q. Shih (ORCID: https://orcid.org/0000-0003-1335-7044)
- Wendy C. S. Ho
- Isabella Almaraz
Institutions
- Cedars-Sinai Medical Center (US)
- Cleveland Clinic (US)
- University of California, Los Angeles (US)
- Cedars-Sinai Smidt Heart Institute (US)
Publication Details
- Journal
- Gastroenterology
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1053/j.gastro.2025.04.028
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Crohn's and Colitis Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases